MARKET

CGEM

CGEM

Cullinan Oncology Inc
NASDAQ
13.28
-0.23
-1.70%
After Hours: 13.41 +0.13 +0.98% 18:14 06/08 EDT
OPEN
13.72
PREV CLOSE
13.51
HIGH
14.25
LOW
12.40
VOLUME
1.74M
TURNOVER
--
52 WEEK HIGH
16.74
52 WEEK LOW
5.68
MARKET CAP
816.16M
P/E (TTM)
-3.5682
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO)
TipRanks · 9h ago
At a glance: stocks gapping up premarket
Seeking Alpha · 12h ago
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data
TipRanks · 12h ago
Cullinan Therapeutics Reiterated as Buy on Promising CLN-978 Data; $30 Price Target Maintained
TipRanks · 12h ago
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Amylyx Pharmaceuticals Inc (AMLX) and Cullinan Management (CGEM)
TipRanks · 12h ago
Cullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug
Dow Jones · 12h ago
Cullinan Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Dow Jones · 12h ago
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target
Benzinga · 13h ago
More
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Webull offers Cullinan Therapeutics Inc stock information, including NASDAQ: CGEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEM stock methods without spending real money on the virtual paper trading platform.